Dear Mr. Vogt:

Please refer to your Supplemental New Drug Applications (sNDAs) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for XALATAN (latanoprost ophthalmic solution), 0.005% as follows:

<table>
<thead>
<tr>
<th>Supplement #</th>
<th>Dated and Received</th>
<th>Provides for</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-045</td>
<td>June 27, 2012</td>
<td>Conversion to the Physicians Labeling Rule (PLR) format</td>
</tr>
<tr>
<td>S-048</td>
<td>September 27, 2013</td>
<td>Revisions to the Precautions, Overdosage and Adverse Reactions section of the Package Insert</td>
</tr>
</tbody>
</table>

We acknowledge receipt of your amendment dated June 10, 2014, in response to our Complete Response letter dated February 12, 2014.

**APPROVAL & LABELING**

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text which is identical to the labeling submitted on June 10, 2014, and with the minor editorial revisions listed below:

In Section 5.1, Pigmentation, the format of the cross-reference to Clinical Studies (14.2) has been amended.

In Section 6.1, Clinical Trials Experience, the word ‘latanoprost’ has been changed to uppercase in both Tables 1 and 2, for consistency.

In Section 17.3, Handling the Container, the cross-reference to the Warnings and Precautions section has been amended.
CONTENT OF LABELING
As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed text for the package insert, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf. The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS
Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels submitted on May 22, 2013, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008). Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Final Printed Carton and Container Labels for approved NDA 20597/S-045 and S-048.” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

REQUIRED PEDIATRIC ASSESSMENTS
Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable. Because none of these criteria apply to your application, you are exempt from this requirement.
REPORTING REQUIREMENTS
We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Michael Puglisi, Regulatory Project Manager at 301-796-0791.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, MD
Deputy Director
Division of Transplant and Ophthalmology Products
Office of Antimicrobial Products
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
Carton and Container Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

WILEY A CHAMBERS
11/25/2014